Pharmacology Pharmacodynamics and Mechanism of Action Questions and Answers

Question 1

A non-competitive antagonist is added to a preparation containing an agonist. How will this affect the agonist's dose-response curve?

Accepted Answer

The maximal effect (Emax) will be reduced, and the EC50 will remain unchanged.

Answer

A non-competitive antagonist binds to a site on the receptor other than the agonist binding site (an allosteric site) or binds irreversibly to the active site. This action prevents the agonist from producing its maximal effect, regardless of the agonist concentration. Therefore, the maximal effect (Emax) is reduced. Because the antagonist does not compete for the same binding site, it does not change the concentration of the agonist required to achieve 50% of the *new* maximal effect, so the EC50 is unchanged.

Question 2

A patient addicted to a full opioid agonist is started on buprenorphine for medication-assisted treatment. Buprenorphine effectively reduces cravings and withdrawal symptoms but has a lower risk of respiratory depression at higher doses compared to the full agonist. This is because buprenorphine acts as a:

Accepted Answer

Partial agonist

Answer

Buprenorphine is a partial agonist at the mu-opioid receptor. This means it binds to and activates the receptor but has lower intrinsic activity than a full agonist. This partial activation is sufficient to alleviate withdrawal symptoms but results in a 'ceiling effect' for respiratory depression, making it safer than full agonists like morphine or methadone.

Question 3

Which of the following statements best describes the clinical significance of a drug's therapeutic index (TI)?

Accepted Answer

It provides a measure of the drug's margin of safety.

Answer

The therapeutic index (TI) is the ratio of the dose that produces toxicity in 50% of the population (TD50) to the dose that produces a clinically desired effect in 50% of the population (ED50). A larger or wider TI indicates a greater margin of safety, meaning there is a larger difference between the effective dose and the toxic dose. Drugs with a narrow TI require careful monitoring to avoid toxicity.

Question 4

Which of the following receptor types has an intrinsic enzymatic domain that is activated upon ligand binding, leading to intracellular signaling cascades through phosphorylation?

Accepted Answer

Enzyme-linked receptors

Answer

Enzyme-linked receptors, such as receptor tyrosine kinases (e.g., the insulin receptor), are transmembrane proteins with an extracellular ligand-binding domain and an intracellular domain that has intrinsic enzyme activity. Upon ligand binding, the receptor dimerizes, activating the intracellular kinase domain, which then phosphorylates itself and other substrate proteins to initiate a signaling cascade.

Question 5

Drug A produces a maximal analgesic effect at a dose of 10 mg. Drug B produces the same maximal analgesic effect at a dose of 50 mg. Drug C, even at its highest tolerated dose of 200 mg, only produces 60% of the maximal analgesic effect of Drugs A and B. Which statement is correct?

Accepted Answer

Drug A is more potent than Drug B, and both are more efficacious than Drug C.

Answer

Potency refers to the amount of drug needed to produce a given effect; Drug A requires a lower dose (10 mg) than Drug B (50 mg) for the same effect, so Drug A is more potent. Efficacy refers to the maximal effect a drug can produce. Drugs A and B can produce the maximal analgesic effect (100% efficacy in this context), while Drug C cannot, meaning Drugs A and B are more efficacious than Drug C.

Pharmacology Practice Test

Pharmacology Practice Test

Pharmacology Pharmacodynamics and Mechanism of Action Questions and Answers